Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio
The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
